Why is Zydus Lifesciences Ltd ?
- Healthy long term growth as Net Sales has grown by an annual rate of 13.79% and Operating profit at 19.95%
- Company has a Debt to Equity ratio (avg) of 0.05 times
- The company has been able to generate a Return on Equity (avg) of 17.49% signifying high profitability per unit of shareholders funds
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 11.88%, its profits have risen by 4.2% ; the PEG ratio of the company is 4.7
- Along with generating 11.88% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
How much should you buy?
- Overall Portfolio exposure to Zydus Lifesci. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Zydus Lifesci. for you?
Low Risk, High Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
At Rs 22,468.50 cr has Grown at 22.31%
At Rs 408.90 cr has Grown at 55.71%
At Rs 1,218.70 cr has Fallen at -30.98%
At Rs 953.07 cr has Fallen at -35.0%
Lowest at 19.13%
Lowest at 12.37 times
Highest at 0.46 times
Lowest at 24.07%
Lowest at Rs 9.42
Here's what is working for Zydus Lifesci.
Net Sales (Rs Cr)
Net Sales (Rs Cr)
Here's what is not working for Zydus Lifesci.
PBT less Other Income (Rs Cr)
PAT (Rs Cr)
Interest Paid (Rs cr)
Operating Profit to Interest
Interest Paid (Rs cr)
Operating Profit to Sales
PBT less Other Income (Rs Cr)
EPS (Rs)
Debt-Equity Ratio






